BMC Cancer

Table 2 Relationship between serum lnc34a expression and clinicopathological characteristics

From: Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

		Serum Lnc34a Expression
Variable	n	Low	High	P
Age
≤ 56	78	40	38	0.577
> 56	79	37	42
Gender
male	142	69	73	0.727
female	15	8	7
HBsAg
negative	28	17	11	0.173
positive	129	60	69
HCV-Ab
negative	152	76	76	0.387
positive	5	1	4
AFP
≤ 20	60	31	29	0.605
> 20	97	46	51
ALT
≤ 40	126	61	65	0.749
> 40	31	16	15
γ-GT
≤ 50	96	49	47	0.530
> 50	61	28	33
Liver cirrhosis
no	34	18	16	0.608
yes	123	59	64
Child-Pugh score
A	151	73	78	0.643
B	6	4	2
Tumor differentiation
I–II	93	43	50	0.396
III–IV	64	34	30
Tumor size, cm
≤ 5	107	49	58	0.233
> 5	50	28	22
Tumor number
single	98	45	53	0.313
multiple	59	32	27
Tumor encapsulation
complete	72	35	37	0.920
none	85	42	43
Vascular invasion
no	112	61	51	0.032
yes	45	16	29
BCLC stage
0-A	99	56	43	0.014
B-C	58	21	37
Lung metastasis
no	134	67	67	0.566
yes	23	10	13
Lymph node metastasis
no	137	68	69	0.701
yes	20	9	11
Bone metastasis
no	139	74	65	0.003
yes	18	3	15

HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC-stage Barcelona Clinic Liver Cancer-stage

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com